

Inorganic Nitrate (NaNO₃) Prevention of Contrast-Associated Acute Kidney Injury

NCT07016074

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Michigan
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (9)

- Planned coronary angiogram or contrast-enhanced CT scan.
- High-risk for contrast-associated acute kidney injury (AKI) with creatine/Glomerular filtration rate (GFR) within 90 days as defined as:
 - Undergoing coronary angiogram with GFR ≤ 45 mL/min/1.73m² OR
 - Undergoing coronary angiogram with GFR ≤ 60 mL/min/1.73m² and concurrent risk of AKI as defined by Hamilton et al. BMC2 risk prediction model e 7%.
- OR

... and 4 more (see full listing online)

Exclusion (10)

- Already fulfilling definition of acute kidney injury prior to contrast exposure by kidney disease improving global outcomes (KDIGO) criteria (absolute increase in creatinine from baseline of 0.3mg/dL or more OR relative increase in creatine of 50% or more from baseline).
- Primary indication for Percutaneous Coronary Intervention (PCI) including acute ST-segment elevation myocardial infarction
- End-stage renal disease actively on dialysis.
- Received any intravenous or intraarterial contrast within five days from planned contrast administration.
- Cardiac arrest within 14 days of planned contrast administration.

... and 5 more (see full listing online)

Locations (1 total)

University of Michigan, Ann Arbor, Michigan, United States

<https://clinicaltrials.gov/study/NCT07016074>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.